ArticleRSC advances2018
The diagnosis of hepatic fibrosis by magnetic resonance and near-infrared imaging using dual-modality nanoparticles.
Article in RSC advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Advancing regenerative medicine with RNA nanotechnology for chronic and end organ diseases.Communications medicine · 2026Review
- The Dual-Faceted Role of Metal-Based Nanomaterials in Hepatic Fibrosis Therapy.International journal of nanomedicine · 2026Review
- Advances in nanotechnology for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease.Asian journal of pharmaceutical sciences · 2025Review
- Nanomedicines in the Treatment of Liver Fibrosis: A Review.International journal of nanomedicine · 2025Review
- Protective Effects of Propolis and Chitosan Nanoparticles against Ibuprofen-Induced Hepatotoxicity in Albino Rats.Diseases (Basel, Switzerland) · 2024Article
- Knockdown of Hyaluronan synthase 2 suppresses liver fibrosis in mice via induction of transcriptomic changes similar to 4MU treatment.Scientific reports · 2024Article
- Advances in Noninvasive Molecular Imaging Probes for Liver Fibrosis Diagnosis.Biomaterials research · 2024Review
- Article
- Therapeutic Effect of Polymeric Nanomicelles Formulation of LY2157299-Galunisertib on CClJournal of personalized medicine · 2022Article
- Biodistribution Profile of Magnetic Nanoparticles in Cirrhosis-Associated Hepatocarcinogenesis in Rats by AC Biosusceptometry.Pharmaceutics · 2022Article
- Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders.Advanced drug delivery reviews · 2021Review
- The Potential Application of Magnetic Nanoparticles for Liver Fibrosis Theranostics.Frontiers in chemistry · 2021Review
- Nanotechnology in Drug Delivery for Liver Fibrosis.Frontiers in molecular biosciences · 2021Review
- Recent Advances in Nanomedicine for the Diagnosis and Therapy of Liver Fibrosis.Nanomaterials (Basel, Switzerland) · 2020Review
- A physical approach for the estimation of the SERS enhancement factor through the enrichment and separation of target molecules using magnetic adsorbents.RSC advances · 2020Article
- Magnetic-Assisted Treatment of Liver Fibrosis.Cells · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic fibrosis (HF), as the only reversible process of chronic liver disease, remains a big diagnostic challenge. Development of noninvasive and effective methods to assess quantitatively early-stage HF is of great clinical importance. Compared with conventional diagnostic methods, near-infrared fluorescence imaging (NIR) and magnetic resonance imaging (MRI) could offer highly sensitive and spatial resolution signals for HF detection. However, precise detection using contrast agents is not possible. Superparamagnetic iron oxide (SPIO) nanoparticles have low toxicity, high sensitivity and excellent biocompatibility. Integration of Fe
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.